

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Reqsted: 06/14/2006
Time Report Reqsted: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

C Number: C20201B
Lock Date: 07/24/2004
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	1	TMT:	0	SEX:	Female	DAY ON TEST:	187
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303051

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver		Inflammation	Minimal
		Pigmentation	Minimal
* Lung	Serosa	Inflammation	Chronic Active, Minimal
Stomach, Forestomach		Squamous Cell Papilloma	
[Squamous Cell Papilloma	TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	2	TMT:	0	SEX:	Female	DAY ON TEST:	183
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303052

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Skin, Soa No Mass	Skin, Control Dermis Spleen	Skin, Control Epidermis Thymus	Skin, Site Of Application
-----------------------------	--------------------------------	-----------------------------------	---------------------------

OBSERVATIONS

* Liver	Clear Cell Focus Inflammation Necrosis	Minimal Minimal
Mesentery [Necrosis TGLs = 2-10]	Necrosis	Moderate
* Skin Note: TGL 1 was from the urogenital area. [Hyperplasia TGLs = 1-10]	Hyperplasia Inflammation	Squamous, Moderate Chronic Active, Mild

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	3	TMT:	0	SEX:	Female	DAY ON TEST:	185
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303053

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver		Inflammation	Minimal
* Lung	Serosa	Inflammation	Chronic Active, Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	4	TMT:	0	SEX:	Female	DAY ON TEST:	185
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303054

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver		Inflammation	Minimal
		Necrosis	Mild
		Pigmentation	Minimal
* Lung	Serosa	Inflammation	Chronic Active, Minimal
	Perivascular	Inflammation	Minimal
Stomach, Forestomach		Squamous Cell Papilloma	
[Squamous Cell Papilloma	TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM: 5

TMT: 0

SEX: Female

DAY ON TEST: 186

DOSE: 0 NG/KG

DISP: Terminal Sacrifice

HISTO: 0303055

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis

Skin, Control Epidermis

OBSERVATIONS

* Liver		Leukemia Erythrocytic Necrosis	Moderate
	[Leukemia Erythrocytic TGLs = 3-4+5]		
* Lung	Serosa	Inflammation Leukemia Erythrocytic	Chronic Active, Minimal
	Skin, Site of Application	Fibrosis	Mild
	[Fibrosis TGLs = 2-11]		
	Skin, SOA No Mass	Inflammation	Chronic Active, Minimal
	[Inflammation TGLs = 2-11]		
	Spleen	Leukemia Erythrocytic	
	[Leukemia Erythrocytic TGLs = 4-4]		
	Thymus	Atrophy	Minimal

Animal Note: TGL 1 = NCL (No Corresponding Lesion)

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	6	TMT:	0	SEX:	Female	DAY ON TEST:	186
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303056

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Ovary	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
* Lung	Alveolar/Bronchiolar Adenoma	
Ovary		
Note: No lesions were found. The cysts were probably bursal cysts which collapsed during processing.		
Skin, Site of Application	Inflammation	Chronic Active, Minimal
	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 1-11]		
Tooth	Odontogenic Tumor	Multiple
[Odontogenic Tumor TGLs = 2-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	7	TMT:	0	SEX:	Female	DAY ON TEST:	185
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303057

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Spleen	Thymus		

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
Skin, SOA No Mass	Inflammation	Chronic Active, Minimal
Stomach, Forestomach	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 2-11]		
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	8	TMT:	0	SEX:	Female	DAY ON TEST:	165
		DOSE:	0 NG/KG	DISP:	Moribund Sacrifice	HISTO:	0303058

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass
Spleen			

OBSERVATIONS

* Liver		Hepatodiaphragmatic Nodule	
		Inflammation	Mild
		Necrosis	Minimal
		Pigmentation	Minimal
	[Hepatodiaphragmatic Nodule TGLs = 2-4]		
* Lung	Interstitialium	Inflammation	Minimal
Thymus		Atrophy	Moderate
Tooth		Odontogenic Tumor	
	[Odontogenic Tumor TGLs = 1-1]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	9	TMT:	0	SEX:	Female	DAY ON TEST:	186
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303059

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Fatty Change	Minimal
	Inflammation	Minimal
Stomach, Forestomach	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 10	TMT: 0	SEX: Female	DAY ON TEST: 183
	DOSE: 0 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303060

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass
Thymus			

OBSERVATIONS

* Liver		Inflammation Pigmentation	Mild Minimal
* Lung	Perivascular Serosa	Inflammation Inflammation	Minimal Chronic Active, Minimal
* Skin		Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal
Note: TGL 1 was from the genital area.			
	[Hyperplasia	TGLs = 1-10]	
	[Inflammation	TGLs = 1-10]	
Spleen		Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	11	TMT:	0	SEX:	Female	DAY ON TEST:	185
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303061

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Stomach, Forestomach	Thymus

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
* Skin	Hyperplasia	Squamous, Minimal

Note: TGL 1 was from the genital area.
[Hyperplasia TGLs = 1-10]

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	12	TMT:	0	SEX:	Female	DAY ON TEST:	74
		DOSE:	0 NG/KG	DISP:	Natural Death	HISTO:	0303062

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
---------	--------------	---------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM: 13	TMT: 0	SEX: Female	DAY ON TEST: 187
	DOSE: 0 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303063

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	14	TMT:	0	SEX:	Female	DAY ON TEST:	81
		DOSE:	0 NG/KG	DISP:	Natural Death	HISTO:	0306064

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
---------	--------------	---------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	15	TMT:	0	SEX:	Female	DAY ON TEST:	183
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303065

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Mild
	Pigmentation	Minimal
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM:	16	TMT:	0	SEX:	Female	DAY ON TEST:	184
		DOSE:	0 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303066

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Skin, Site Of Application	Lymph Node, Mesenteric Skin, Soa No Mass	Skin, Control Dermis Spleen	Skin, Control Epidermis Thymus
-------------------------------------	---	--------------------------------	-----------------------------------

OBSERVATIONS

* Liver	Hematopoietic Cell Proliferation	Minimal
	Inflammation	Minimal
	Necrosis	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 17	TMT: 0	SEX: Female	DAY ON TEST: 186
	DOSE: 0 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303067

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Spleen
------------------	----------------------	-------------------------	--------

OBSERVATIONS

* Liver	Inflammation Necrosis	Minimal Minimal
Salivary Glands [Squamous Cell Carcinoma TGLs = 2-11]	Squamous Cell Carcinoma	
Skin, Site of Application [Hyperplasia TGLs = 1-10]	Hyperplasia Inflammation	Squamous, Moderate Chronic Active, Minimal
Skin, SOA No Mass	Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal
Stomach, Forestomach [Squamous Cell Papilloma TGLs = 3-12+13]	Squamous Cell Papilloma	Multiple
Stomach, Glandular Glands	Hyperplasia	Mild

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM: 18	TMT: 0	SEX: Female	DAY ON TEST: 186
	DOSE: 0 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303068

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Thymus		

OBSERVATIONS

* Liver	Inflammation	Minimal
Spleen	Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 19	TMT: 0	SEX: Female	DAY ON TEST: 184
	DOSE: 0 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303069

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis Thymus	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass
--------------------------------	-------------------------	---------------------------	-------------------

OBSERVATIONS

* Liver		Inflammation	Minimal
* Lung	Serosa	Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Mild

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 20	TMT: 0	SEX: Female	DAY ON TEST: 184
	DOSE: 0 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303070

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass
Spleen			

OBSERVATIONS

* Liver		Inflammation Pigmentation	Moderate Minimal
* Lung	Serosa	Inflammation	Chronic Active, Minimal
* Skin		Fibrosis Hyperplasia Inflammation Ulcer	Mild Squamous, Mild Chronic Active, Minimal Minimal
Note: TGL 1 was from the genital area. [Fibrosis TGLs = 1-10]			
Thymus		Atrophy	Marked
Tooth		Odontogenic Tumor	
	[Odontogenic Tumor TGLs = 2-1]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 201	TMT: 1	SEX: Female	DAY ON TEST: 43
	DOSE: 360 NG/KG	DISP: Moribund Sacrifice	HISTO: 0303111

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Skin, Soa No Mass

OBSERVATIONS

* Liver		Lymphoma Malignant
* Lung		Lymphoma Malignant
Lymph Node	Deep Cervical	Lymphoma Malignant
	Renal	Lymphoma Malignant
	Iliac	Lymphoma Malignant
	[Lymphoma Malignant TGLs = 5-12]	
	[Lymphoma Malignant TGLs = 3-11]	
	[Lymphoma Malignant TGLs = 1-10]	
Lymph Node, Mandibular		Lymphoma Malignant
	[Lymphoma Malignant TGLs = 4-2]	
Lymph Node, Mesenteric		Lymphoma Malignant
	[Lymphoma Malignant TGLs = 7-5]	
Spleen		Lymphoma Malignant
	[Lymphoma Malignant TGLs = 2-4]	
Thymus		Lymphoma Malignant
	[Lymphoma Malignant TGLs = 6-13]	

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	202	TMT:	1	SEX:	Female	DAY ON TEST:	187
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303112

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	203	TMT:	1	SEX:	Female	DAY ON TEST:	183
		DOSE:	360 NG/KG	DISP:	Natural Death	HISTO:	0303113

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen		

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation	Minimal
		Necrosis	Minimal
Ovary		Teratoma Benign	
	[Teratoma Benign TGLs = 1-7]		
Thymus		Atrophy	Mild

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	204	TMT:	1	SEX:	Female	DAY ON TEST:	183
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303114

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 205	TMT: 1	SEX: Female	DAY ON TEST: 185
	DOSE: 360 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303115

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Minimal
* Skin	Squamous Cell Papilloma	
Note: TGL 1 was from the genital area.		
[Squamous Cell Papilloma TGLs = 1-10]		
Stomach, Forestomach	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 2-11]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	206	TMT:	1	SEX:	Female	DAY ON TEST:	185
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303116

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Mild
* Skin	Inflammation	Chronic Active, Mild
	Squamous Cell Papilloma	

Note: TGL 1 was from the abdominal area (inguinal).
[Inflammation TGLs = 1-10]
[Squamous Cell Papilloma TGLs = 1-10]

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	207	TMT:	1	SEX:	Female	DAY ON TEST:	148
		DOSE:	360 NG/KG	DISP:	Moribund Sacrifice	HISTO:	0303117

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis Thymus	Skin, Control Epidermis	Skin, Site Of Application
------------------	--------------------------------	-------------------------	---------------------------

OBSERVATIONS

* Liver	Inflammation Necrosis Pigmentation	Mild Minimal Minimal
Lymph Node, Mandibular [Hyperplasia TGLs = 2-2]	Hyperplasia	Plasma Cell, Moderate
Skin, SOA No Mass	Inflammation	Chronic Active, Minimal
Tooth [Odontogenic Tumor TGLs = 1-10]	Odontogenic Tumor	

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	208	TMT:	1	SEX:	Female	DAY ON TEST:	185
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303118

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application	Spleen
Thymus			

OBSERVATIONS

* Liver		Inflammation	Mild
		Pigmentation	Minimal
* Lung	Alveolar Epith	Hyperplasia	Moderate
Skin, SOA No Mass		Hyperplasia	Squamous, Minimal
Stomach, Forestomach		Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma	TGLs = 1-10+11]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	209	TMT:	1	SEX:	Female	DAY ON TEST:	82
		DOSE:	360 NG/KG	DISP:	Natural Death	HISTO:	0303119

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	210	TMT:	1	SEX:	Female	DAY ON TEST:	184
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303120

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Minimal
	Pigmentation	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 211	TMT: 1	SEX: Female	DAY ON TEST: 183
	DOSE: 360 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303121

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Fatty Change	Minimal
	Inflammation	Minimal
	Pigmentation	Minimal
* Skin	Hyperplasia	Squamous, Mild
Note: TGL 1 was from the genital area.		
[Hyperplasia TGLs = 1-10]		
Stomach, Forestomach	Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma TGLs = 2-11+12]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM: 212	TMT: 1	SEX: Female	DAY ON TEST: 186
	DOSE: 360 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303122

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Spleen	Thymus		

OBSERVATIONS

* Liver	Inflammation	Minimal
* Skin	Squamous Cell Papilloma	
Note: TGL 1 was from the genital area.		
[Squamous Cell Papilloma TGLs = 1-10]		
Skin, SOA No Mass	Hyperplasia	Squamous, Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 213	TMT: 1	SEX: Female	DAY ON TEST: 55
	DOSE: 360 NG/KG	DISP: Natural Death	HISTO: 0303123

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Site Of Application	Skin, Soa No Mass	Spleen
Thymus			

OBSERVATIONS

* Liver	Inflammation	Minimal
Skin, Control Dermis	Inflammation	Chronic Active, Minimal
Skin, Control Epidermis	Hyperplasia	Squamous, Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 214	TMT: 1	SEX: Female	DAY ON TEST: 184
	DOSE: 360 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303124

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis Thymus	Skin, Control Epidermis	Skin, Site Of Application
------------------	--------------------------------	-------------------------	---------------------------

OBSERVATIONS

* Liver	Fatty Change Inflammation Pigmentation	Minimal Minimal Minimal
Skin, SOA No Mass	Inflammation	Chronic Active, Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 215	TMT: 1	SEX: Female	DAY ON TEST: 184
	DOSE: 360 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303125

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Epidermis	Skin, Site Of Application	Spleen	Thymus
-------------------------	---------------------------	--------	--------

OBSERVATIONS

* Liver		Inflammation	Minimal
* Lung	Alveolus	Infiltration Cellular	Histiocyte, Minimal
* Skin		Hyperplasia	Squamous, Mild
		Inflammation	Chronic Active, Moderate
		Keratoacanthoma	Multiple
		Squamous Cell Papilloma	Multiple

Note: TGL 1 was from the genital area.

Note: TGL 2-6 (slides 11-15) were from the ventral thoracic area and were in a cluster. Dysplastic cells are present in the stalk of the tumors on slides 12 and 14

[Hyperplasia TGLs = 1-10]

[Keratoacanthoma TGLs = 3-12;5-14]

[Squamous Cell Papilloma TGLs = 2,3,4,6-11+12+13+15]

Skin, Control Dermis		Inflammation	Chronic Active, Minimal
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	216	TMT:	1	SEX:	Female	DAY ON TEST:	172
		DOSE:	360 NG/KG	DISP:	Moribund Sacrifice	HISTO:	0303126

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis Thymus	Skin, Control Epidermis	Skin, Site Of Application
------------------	--------------------------------	-------------------------	---------------------------

OBSERVATIONS

* Liver	Inflammation Pigmentation	Minimal Minimal
Lymph Node, Mandibular [Hyperplasia TGLs = 2-2]	Hyperplasia	Plasma Cell, Moderate
Skin, SOA No Mass	Hyperplasia	Squamous, Minimal
Tooth [Odontogenic Tumor TGLs = 1-10]	Odontogenic Tumor	

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	217	TMT:	1	SEX:	Female	DAY ON TEST:	186
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303127

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
---------	--------------	---------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	218	TMT:	1	SEX:	Female	DAY ON TEST:	185
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303128

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Bone	* Lung	Skin, Control Dermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Mild
	Necrosis	Minimal
	Pigmentation	Minimal
Skin, Control Epidermis	Hyperplasia	Squamous, Minimal
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 2-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM:	219	TMT:	1	SEX:	Female	DAY ON TEST:	145
		DOSE:	360 NG/KG	DISP:	Natural Death	HISTO:	0303129

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis

Skin, Control Epidermis

Skin, Site Of Application

MISSING

Thymus

OBSERVATIONS

* Liver	[Leukemia Erythrocytic TGLs = 1-4+10]	Leukemia Erythrocytic	
* Lung		Leukemia Erythrocytic	
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen	[Leukemia Erythrocytic TGLs = 2-4]	Leukemia Erythrocytic	

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	220	TMT:	1	SEX:	Female	DAY ON TEST:	185
		DOSE:	360 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303130

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
---------	--------------	---------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	221	TMT:	2	SEX:	Female	DAY ON TEST:	94
		DOSE:	1210 NG/KG	DISP:	Moribund Sacrifice	HISTO:	0303131

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Thymus		

OBSERVATIONS

Eye	Antr Chamber, Cornea	Inflammation	Suppurative, Moderate
[Inflammation	TGLs = 1-9]		
* Liver		Inflammation	Minimal
		Pigmentation	Minimal
Spleen		Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 222	TMT: 2	SEX: Female	DAY ON TEST: 184
	DOSE: 1210 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303132

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
* Skin	Fibrosis	Mild

Note: TGL 1 was from the genital area.
[Fibrosis TGLs = 1-10]

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM: 223 TMT: 2
DOSE: 1210 NG/KG

SEX: Female
DISP: Natural Death

DAY ON TEST: 81
HISTO: 0303133

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Liver
Skin, Site Of Application

* Lung
Skin, Soa No Mass

Skin, Control Dermis
Spleen

Skin, Control Epidermis
Thymus

OBSERVATIONS

* Skin Hyperplasia Inflammation Squamous, Minimal
Chronic Active, Minimal

Note: TGL 1 was from the back in the abdominal region.
[Hyperplasia TGLs = 1-10]

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	224	TMT:	2	SEX:	Female	DAY ON TEST:	184
		DOSE:	1210 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303134

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Thymus		

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
Spleen	Hematopoietic Cell Proliferation	Minimal
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 225	TMT: 2	SEX: Female	DAY ON TEST: 183
	DOSE: 1210 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303135

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Minimal
	Pigmentation	Minimal
Stomach, Forestomach	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 2-11]		
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	227	TMT:	2	SEX:	Female	DAY ON TEST:	102
		DOSE:	1210 NG/KG	DISP:	Natural Death	HISTO:	0303137

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 228	TMT: 2	SEX: Female	DAY ON TEST: 114
	DOSE: 1210 NG/KG	DISP: Natural Death	HISTO: 0303138

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis Thymus	Skin, Control Epidermis	Skin, Soa No Mass
------------------	--------------------------------	-------------------------	-------------------

OBSERVATIONS

* Liver	Inflammation Pigmentation	Minimal Minimal
Skin, Site of Application	Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal
[Hyperplasia TGLs = 1-10] [Inflammation TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	229	TMT:	2	SEX:	Female	DAY ON TEST:	186
		DOSE:	1210 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303139

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass			

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
Spleen	Hematopoietic Cell Proliferation	Minimal
Thymus	Atrophy	Mild
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 1,2-1+10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 230	TMT: 2	SEX: Female	DAY ON TEST: 184
	DOSE: 1210 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303140

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver		Inflammation Necrosis	Minimal Minimal
* Lung	Alveolar Epith	Hyperplasia	Minimal
* Skin		Inflammation Squamous Cell Papilloma	Chronic Active, Minimal
Note: TGL 2 was from the genital area. [Squamous Cell Papilloma TGLs = 2-11]			
Skin, Site of Application		Hyperplasia Inflammation Ulcer	Squamous, Moderate Chronic Active, Mild Minimal
	[Hyperplasia TGLs = 1-10]		
Spleen		Hematopoietic Cell Proliferation	Minimal
Thymus		Atrophy	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	231	TMT:	2	SEX:	Female	DAY ON TEST:	183
		DOSE:	1210 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303141

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
---------	--------------	---------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	232	TMT:	2	SEX:	Female	DAY ON TEST:	69
		DOSE:	1210 NG/KG	DISP:	Natural Death	HISTO:	0303142

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
---------	--------------	---------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	233	TMT:	2	SEX:	Female	DAY ON TEST:	183
		DOSE:	1210 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303143

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
------------------	----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation Inflammation Necrosis	Minimal Minimal Minimal
Skin, Site of Application		Inflammation Squamous Cell Papilloma	Chronic Active, Mild
	[Squamous Cell Papilloma TGLs = 3-11]		
Spleen		Hematopoietic Cell Proliferation	Minimal
Tooth		Odontogenic Tumor	
	[Odontogenic Tumor TGLs = 1-1]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	234	TMT:	2	SEX:	Female	DAY ON TEST:	127
		DOSE:	1210 NG/KG	DISP:	Moribund Sacrifice	HISTO:	0303144

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
------------------	----------------------	-------------------------	-------------------

MISSING
Thymus

OBSERVATIONS

* Liver	Pigmentation	Minimal
* Skin	Fibrosis	Minimal
Note: TGL 1 was from the genital area. [Fibrosis TGLs = 1-11]		
Skin, Site of Application	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 2-12]		
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 3-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 235	TMT: 2	SEX: Female	DAY ON TEST: 117
	DOSE: 1210 NG/KG	DISP: Natural Death	HISTO: 0303145

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
----------------------	-------------------------	---------------------------

OBSERVATIONS

Brain	Meninges Meninges	Hemorrhage Leukemia Erythrocytic	Mild
	[Hemorrhage TGLs = 1-14] [Leukemia Erythrocytic TGLs = 1-14]		
Kidney		Leukemia Erythrocytic	
	[Leukemia Erythrocytic TGLs = 5-4]		
* Liver		Leukemia Erythrocytic	
	[Leukemia Erythrocytic TGLs = 3,6,7-11+12+13]		
* Lung		Leukemia Erythrocytic	
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Leukemia Erythrocytic	
	[Leukemia Erythrocytic TGLs = 2,4-10]		
Thymus		Atrophy	Marked

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	236	TMT:	2	SEX:	Female	DAY ON TEST:	86
		DOSE:	1210 NG/KG	DISP:	Moribund Sacrifice	HISTO:	0303146

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Liver Skin, Site Of Application	* Lung Skin, Soa No Mass	Skin, Control Dermis Spleen	Skin, Control Epidermis
--------------------------------------	-----------------------------	--------------------------------	-------------------------

OBSERVATIONS

Thymus	Atrophy	Marked
--------	---------	--------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	237	TMT:	2	SEX:	Female	DAY ON TEST:	185
		DOSE:	1210 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303147

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen		

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Minimal
	Pigmentation	Minimal
Thymus	Atrophy	Mild
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 238	TMT: 2	SEX: Female	DAY ON TEST: 183
	DOSE: 1210 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303148

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Spleen
------------------	----------------------	-------------------------	--------

OBSERVATIONS

Gallbladder	Inflammation	Granulomatous, Moderate
Note: There was granulomatous inflammation in the wall of the gallbladder with mineralizaion and adhesions to the adjacent liver.		
* Liver	Pigmentation	Mild
* Skin	Squamous Cell Papilloma	
Note: TGL 2 was from the genital area. [Squamous Cell Papilloma TGLs = 2-11]		
Skin, Site of Application	Hyperplasia Inflammation	Squamous, Mild Chronic Active, Minimal
[Hyperplasia TGLs = 1-10] [Inflammation TGLs = 1-10]		
Skin, SOA No Mass	Inflammation	Chronic Active, Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 239	TMT: 2	SEX: Female	DAY ON TEST: 184
	DOSE: 1210 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303149

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
------------------	----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver	Fatty Change	Minimal
	Inflammation	Minimal
	Necrosis	Mild
	Pigmentation	Minimal
Skin, Site of Application	Inflammation	Chronic Active, Minimal
	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 1-10]		
Stomach, Forestomach	Squamous Cell Papilloma	
[Squamous Cell Papilloma TGLs = 2-11]		
Thymus	Atrophy	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 240	TMT: 2	SEX: Female	DAY ON TEST: 187
	DOSE: 1210 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303150

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis Thymus	Skin, Control Epidermis	Skin, Soa No Mass
------------------	--------------------------------	-------------------------	-------------------

OBSERVATIONS

* Liver	Fatty Change Inflammation Necrosis	Minimal Mild Mild
Skin, Site of Application [Squamous Cell Papilloma TGLs = 1-10]	Squamous Cell Papilloma	

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 241	TMT: 3	SEX: Female	DAY ON TEST: 185
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303151

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Skin, Soa No Mass	Skin, Control Dermis Spleen	Skin, Control Epidermis Thymus	Skin, Site Of Application
-----------------------------	--------------------------------	-----------------------------------	---------------------------

OBSERVATIONS

* Liver	Inflammation Necrosis Pigmentation	Mild Minimal Minimal
---------	--	----------------------------

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 242	TMT: 3	SEX: Female	DAY ON TEST: 185
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303152

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Thymus
----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Fatty Change Inflammation Necrosis Pigmentation	Minimal Mild Minimal Minimal
* Lung	Perivascular	Inflammation	Moderate
Note: The inflammation in the lung was perivascular with a subintimal reaction in some that partially occluded the lumen.			
* Skin		Squamous Cell Papilloma	
Note: TGL 1 was from the genital area. [Squamous Cell Papilloma TGLs = 1-10]			
Skin, Site of Application		Inflammation Squamous Cell Papilloma	Chronic Active, Mild Multiple
[Squamous Cell Papilloma TGLs = 2,3,4,5-11+12+13+14]			
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	243	TMT:	3	SEX:	Female	DAY ON TEST:	183
		DOSE:	3600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303153

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver		Inflammation	Mild
		Pigmentation	Minimal
Skin, Site of Application		Inflammation	Chronic Active, Mild
		Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma	TGLs = 1,2,3,4,5-10+11+12+13+14]		
Stomach, Forestomach		Squamous Cell Papilloma	
[Squamous Cell Papilloma	TGLs = 6-15]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 244	TMT: 3	SEX: Female	DAY ON TEST: 183
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303154

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
------------------	----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver		Inflammation Necrosis Pigmentation	Minimal Mild Minimal
Skin, Site of Application		Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Chronic Active, Mild Multiple
	[Squamous Cell Carcinoma TGLs = 3-12] [Squamous Cell Papilloma TGLs = 1,2,3,4,5-10+11+12+13+14]		
Spleen		Hematopoietic Cell Proliferation	Mild
Stomach, Forestomach		Squamous Cell Papilloma	
	[Squamous Cell Papilloma TGLs = 6-15]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 245	TMT: 3	SEX: Female	DAY ON TEST: 171
	DOSE: 3600 NG/KG	DISP: Natural Death	HISTO: 0303155

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Liver Thymus	* Lung	Skin, Control Dermis	Skin, Control Epidermis
-------------------	--------	----------------------	-------------------------

OBSERVATIONS

Pancreas	Artery	Inflammation Necrosis	Chronic Active, Marked Moderate
	[Inflammation TGLs = 7-15] [Necrosis TGLs = 7-15]		
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Papilloma	Squamous, Mild Chronic Active, Mild Multiple
	[Squamous Cell Papilloma TGLs = 1,2,3,4,5-10+11+12+13+14]		
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Mild

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 246	TMT: 3	SEX: Female	DAY ON TEST: 186
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303156

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
------------------	----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
Skin, Site of Application	Inflammation	Chronic Active, Mild
	Keratoacanthoma	
	Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma TGLs = 1,2,3,4-10+11+12+13]		
Spleen	Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 247	TMT: 3	SEX: Female	DAY ON TEST: 186
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303157

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Thymus
----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Inflammation	Minimal
* Lung	Interstitial	Inflammation	Minimal
* Skin		Squamous Cell Papilloma	
Note: TGL 1 was from the genital area.			
	[Squamous Cell Papilloma TGLs = 1-10]		
Skin, Site of Application		Inflammation Squamous Cell Papilloma	Chronic Active, Mild Multiple
	[Squamous Cell Papilloma TGLs = 2,3,4,5,6-11+12+13+14+15]		
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Minimal
Stomach, Forestomach		Squamous Cell Papilloma	
	[Squamous Cell Papilloma TGLs = 7-16]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 248	TMT: 3	SEX: Female	DAY ON TEST: 121
	DOSE: 3600 NG/KG	DISP: Moribund Sacrifice	HISTO: 0303158

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Spleen
--------	----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Inflammation Pigmentation	Minimal Minimal
Skin, Site of Application		Inflammation Squamous Cell Papilloma	Chronic Active, Mild
[Squamous Cell Papilloma TGLs = 1-10]			
Skin, SOA No Mass		Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal
Thymus		Atrophy	Marked
Tooth		Odontogenic Tumor	
[Odontogenic Tumor TGLs = 2-1]			

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 249	TMT: 3	SEX: Female	DAY ON TEST: 186
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303159

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Spleen
------------------	----------------------	-------------------------	--------

OBSERVATIONS

* Liver	Inflammation Pigmentation	Minimal Minimal
* Skin Note: TGL 1 and 2 were from the genital area. [Squamous Cell Papilloma TGLs = 1,2-10+11]	Squamous Cell Papilloma	Multiple
Skin, Site of Application [Squamous Cell Carcinoma TGLs = 4,5-13+14] [Squamous Cell Papilloma TGLs = 3,6,7-12+15+16]	Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Mild Chronic Active, Mild Multiple Multiple
Skin, SOA No Mass	Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 250	TMT: 3	SEX: Female	DAY ON TEST: 187
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303160

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
------------------	----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation Inflammation	Minimal Minimal
* Skin		Squamous Cell Papilloma	
	Note: TGL 1 was from the genital area. [Squamous Cell Papilloma TGLs = 1-10]		
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Papilloma	Squamous, Mild Chronic Active, Mild Multiple
	[Squamous Cell Papilloma TGLs = 2,3,4,5,6-11+12+13+14+14A+15]		
Spleen		Hematopoietic Cell Proliferation	Mild
	[Hematopoietic Cell Proliferation TGLs = 7-4]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 251	TMT: 3	SEX: Female	DAY ON TEST: 183
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303161

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver		Inflammation Pigmentation	Minimal Minimal
Mesentery	Fat	Necrosis	Moderate
	[Necrosis TGLs = 6-15]		
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Mild Chronic Active, Mild Multiple Multiple
	[Squamous Cell Carcinoma TGLs = 3,4-12+13] [Squamous Cell Papilloma TGLs = 1,2,5-10+11+14]		
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Minimal
Uterus		Atrophy	Mild
	[Atrophy TGLs = 7-7]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 252	TMT: 3	SEX: Female	DAY ON TEST: 183
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303162

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation	Moderate
		Inflammation	Minimal
		Necrosis	Minimal
		Pigmentation	Minimal
Mesentery	Artery	Thrombosis	Marked
	[Thrombosis TGLs = 3-12]		
Skin, Site of Application		Inflammation	Chronic Active, Mild
		Squamous Cell Papilloma	Multiple
	[Squamous Cell Papilloma TGLs = 1,2-10+11]		
Skin, SOA No Mass		Hyperplasia	Squamous, Minimal
Spleen		Hematopoietic Cell Proliferation	Marked
		Necrosis	Moderate
	[Hematopoietic Cell Proliferation TGLs = 4-4]		
	[Necrosis TGLs = 3-12]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	253	TMT:	3	SEX:	Female	DAY ON TEST:	112
		DOSE:	3600 NG/KG	DISP:	Natural Death	HISTO:	0303163

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver		Leukemia Erythrocytic	
	[Leukemia Erythrocytic TGLs = 3-3+11]		
* Lung		Leukemia Erythrocytic	
Skin, Site of Application		Inflammation	Chronic Active, Minimal
	[Squamous Cell Papilloma TGLs = 1-10]	Squamous Cell Papilloma	
Spleen		Leukemia Erythrocytic	
	[Leukemia Erythrocytic TGLs = 2,6-4+13]		
Stomach, Forestomach		Squamous Cell Papilloma	
	[Squamous Cell Papilloma TGLs = 4-12]		
Thymus		Atrophy	Marked

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 254	TMT: 3	SEX: Female	DAY ON TEST: 185
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303164

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Spleen
------------------	----------------------	-------------------------	--------

OBSERVATIONS

* Liver	Inflammation Pigmentation	Minimal Minimal
Skin, Site of Application	Inflammation Squamous Cell Carcinoma	Chronic Active, Mild
[Squamous Cell Carcinoma TGLs = 1-10]		
Skin, SOA No Mass	Inflammation	Chronic Active, Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 255	TMT: 3	SEX: Female	DAY ON TEST: 184
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303165

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver		Inflammation Necrosis Pigmentation	Minimal Minimal Minimal
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Moderate Chronic Active, Mild Multiple Multiple
	[Squamous Cell Carcinoma TGLs = 3,5-12,14]		
	[Squamous Cell Papilloma TGLs = 1,2,3,4,5-10+11+12+13+14]		
Spleen		Hematopoietic Cell Proliferation	Mild
Stomach, Forestomach		Squamous Cell Papilloma	
	[Squamous Cell Papilloma TGLs = 6-15]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA

TEF TRANSGENICS (PCB 126)

CAS Number: 57465-28-8

Date Report Requested: 06/14/2006

Time Report Requested: 15:08:25

First Dose M/F: NA / 04/21/03

Lab: BAT

ANIMAL NUM: 256 TMT: 3
DOSE: 3600 NG/KG

SEX: Female
DISP: Moribund Sacrifice

DAY ON TEST: 93
HISTO: 0303166

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Site Of Application
Skin, Soa No Mass	Spleen	Thymus	

OBSERVATIONS

* Liver	Inflammation	Minimal
---------	--------------	---------

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 257	TMT: 3	SEX: Female	DAY ON TEST: 187
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303167

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver		Inflammation Pigmentation	Minimal Minimal
* Skin		Inflammation Squamous Cell Papilloma	Chronic Active, Mild
Note: TGL 1 was from the genital area.			
			[Inflammation TGLs = 1-10]
			[Squamous Cell Papilloma TGLs = 1-10]
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Mild Chronic Active, Mild
			Multiple
			[Squamous Cell Carcinoma TGLs = 7-16]
			[Squamous Cell Papilloma TGLs = 2,3,4,5,6-11+12+13+14+15]
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	258	TMT:	3	SEX:	Female	DAY ON TEST:	183
		DOSE:	3600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303168

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Spleen	Skin, Control Dermis Thymus	Skin, Control Epidermis	Skin, Soa No Mass
------------------	--------------------------------	-------------------------	-------------------

OBSERVATIONS

* Liver	Inflammation Pigmentation	Minimal Minimal
Skin, Site of Application	Hyperplasia Inflammation Squamous Cell Papilloma	Squamous, Moderate Chronic Active, Minimal Multiple
[Hyperplasia TGLs = 3-12] [Squamous Cell Papilloma TGLs = 1,2-10+11]		
Stomach, Forestomach [Squamous Cell Papilloma TGLs = 4-13]	Squamous Cell Papilloma	

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 259	TMT: 3	SEX: Female	DAY ON TEST: 187
	DOSE: 3600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303169

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver		Inflammation	Minimal
		Necrosis	Minimal
		Pigmentation	Minimal
Skin, Site of Application		Hyperplasia	Squamous, Moderate
		Inflammation	Chronic Active, Mild
		Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma	TGLs = 1,2,3,4,5-11+12+13+14+15]		
Tooth		Odontogenic Tumor	
[Odontogenic Tumor	TGLs = 6-10]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	260	TMT:	3	SEX:	Female	DAY ON TEST:	185
		DOSE:	3600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303170

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver		Inflammation	Minimal
Skin, Site of Application		Inflammation	Chronic Active, Mild
		Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma	TGLs = 1,2-10+11]		
Stomach, Forestomach		Squamous Cell Papilloma	
[Squamous Cell Papilloma	TGLs = 3-12]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	261	TMT:	4	SEX:	Female	DAY ON TEST:	185
		DOSE:	7600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303171

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
Skin, Site of Application	Hyperplasia	Squamous, Mild
	Inflammation	Chronic Active, Mild
	Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma TGLs = 1,2,3,4,5-10+11+12]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 262	TMT: 4	SEX: Female	DAY ON TEST: 186
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303172

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Thymus
----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation Inflammation	Minimal Mild
* Lung	Perivascular	Inflammation	Minimal
Salivary Glands		Squamous Cell Carcinoma	
	[Squamous Cell Carcinoma TGLs = 8-2]		
* Skin		Hyperplasia	Squamous, Marked
	Note: TGL 6 was from the genital area. [Hyperplasia TGLs = 6-13]		
Skin, Site of Application		Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Chronic Active, Mild Multiple
	[Squamous Cell Carcinoma TGLs = 5-12] [Squamous Cell Papilloma TGLs = 1,2,3,4-10+11+12]		
Skin, SOA No Mass		Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Mild
	[Hematopoietic Cell Proliferation TGLs = 7-4]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 263	TMT: 4	SEX: Female	DAY ON TEST: 187
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303173

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus
--------	----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation	Minimal
		Inflammation	Mild
		Pigmentation	Minimal
Skin, Site of Application		Hyperplasia	Squamous, Moderate
		Inflammation	Chronic Active, Mild
		Squamous Cell Carcinoma	
		Squamous Cell Papilloma	Multiple
	[Squamous Cell Carcinoma TGLs = 4-11]		
	[Squamous Cell Papilloma TGLs = 1,2,3,5-10+11+12]		
Skin, SOA No Mass		Hyperplasia	Squamous, Minimal
		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Minimal
Stomach, Forestomach		Squamous Cell Papilloma	
	[Squamous Cell Papilloma TGLs = 6-13]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 264	TMT: 4	SEX: Female	DAY ON TEST: 187
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303174

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Epidermis Thymus

OBSERVATIONS

* Liver		Inflammation	Mild
		Necrosis	Mild
* Lung	Serosa	Inflammation	Chronic Active, Minimal
Skin, Control Dermis		Inflammation	Chronic Active, Minimal
Skin, Site of Application		Hyperplasia	Squamous, Marked
		Inflammation	Chronic Active, Mild
		Squamous Cell Carcinoma	
		Squamous Cell Papilloma	Multiple
	[Squamous Cell Carcinoma TGLs = 5-14]		
	[Squamous Cell Papilloma TGLs = 1,2,3,4,5-10+11+12+13+14]		
Spleen		Hematopoietic Cell Proliferation	Minimal
Stomach, Forestomach		Squamous Cell Papilloma	
	[Squamous Cell Papilloma TGLs = 6-15]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 265	TMT: 4	SEX: Female	DAY ON TEST: 183
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303175

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Thymus
----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation Inflammation Necrosis	Minimal Mild Mild
* Lung	Interstitialium	Inflammation	Minimal
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Moderate Chronic Active, Mild Multiple
	[Squamous Cell Carcinoma TGLs = 5-10] [Squamous Cell Papilloma TGLs = 1,2,3,4-10+11]		
Skin, SOA No Mass		Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal
Spleen	[Hematopoietic Cell Proliferation TGLs = 6-4]	Hematopoietic Cell Proliferation	Mild

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 267	TMT: 4	SEX: Female	DAY ON TEST: 172
	DOSE: 7600 NG/KG	DISP: Moribund Sacrifice	HISTO: 0303177

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis
--------	----------------------	-------------------------

OBSERVATIONS

* Liver	Inflammation	Minimal
	Necrosis	Minimal
Lymph Node, Mandibular	Hyperplasia	Plasma Cell, Moderate
[Hyperplasia TGLs = 1-2]		
Skin, Site of Application	Hyperplasia	Squamous, Mild
	Inflammation	Chronic Active, Mild
	Squamous Cell Papilloma	Multiple
[Squamous Cell Papilloma TGLs = 3,4-11+12+13]		
Skin, SOA No Mass	Inflammation	Chronic Active, Minimal
Spleen	Hematopoietic Cell Proliferation	Minimal
Thymus	Atrophy	Minimal
Tooth	Odontogenic Tumor	
[Odontogenic Tumor TGLs = 2-10]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 269	TMT: 4	SEX: Female	DAY ON TEST: 184
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303179

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver		Inflammation Necrosis Pigmentation	Minimal Minimal Minimal
Skin, Site of Application		Hyperplasia Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Moderate Mast Cell, Mild Chronic Active, Mild Multiple
	[Squamous Cell Carcinoma TGLs = 3-13]		
	[Squamous Cell Papilloma TGLs = 2,4,5,6-11+12+13]		
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Mild
Stomach, Forestomach		Squamous Cell Papilloma	Multiple
	[Squamous Cell Papilloma TGLs = 7-14]		
Tooth		Odontogenic Tumor	
	[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	270	TMT:	4	SEX:	Female	DAY ON TEST:	187
		DOSE:	7600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303180

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus
--------	----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Fatty Change Hematopoietic Cell Proliferation Inflammation Necrosis	Minimal Minimal Mild Mild
Skin, Site of Application		Inflammation Squamous Cell Papilloma	Chronic Active, Mild Multiple
[Squamous Cell Papilloma TGLs = 1,2,3,4,5,7-10+11+13]			
Skin, SOA No Mass		Hyperplasia Inflammation	Squamous, Minimal Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Moderate
[Hematopoietic Cell Proliferation TGLs = 8-4]			

Animal Note: TGL 6 = NCL (No Corresponding Lesion)

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 271	TMT: 4	SEX: Female	DAY ON TEST: 184
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303181

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation Inflammation	Minimal Minimal
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Moderate Chronic Active, Mild Multiple
	[Squamous Cell Carcinoma TGLs = 1-10] [Squamous Cell Papilloma TGLs = 2,3,4,5-11+12+13]		
Spleen		Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	272	TMT:	4	SEX:	Female	DAY ON TEST:	184
		DOSE:	7600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303182

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis Skin, Control Epidermis

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation	Minimal
		Inflammation	Mild
		Necrosis	Minimal
		Pigmentation	Minimal
* Lung	Interstitialium	Inflammation	Mild
* Skin		Squamous Cell Papilloma	
	Note: TGL 2 was from the abdominal area. [Squamous Cell Papilloma TGLs = 2-11]		
Skin, Site of Application		Inflammation	Chronic Active, Mild
		Squamous Cell Papilloma	Multiple
	[Squamous Cell Papilloma TGLs = 3,4,5,6,7-12+13+14]		
Spleen		Hematopoietic Cell Proliferation	Moderate
	[Hematopoietic Cell Proliferation TGLs = 8-4]		
Thymus		Atrophy	Moderate
Tooth		Odontogenic Tumor	
	[Odontogenic Tumor TGLs = 1-10]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 273	TMT: 4	SEX: Female	DAY ON TEST: 184
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303183

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver		Fatty Change Inflammation Necrosis Pigmentation	Minimal Minimal Minimal Minimal
* Lung	Interstitialium	Inflammation	Minimal
* Skin		Hyperplasia Inflammation Ulcer	Squamous, Moderate Chronic Active, Mild Mild
<p>Note: The chin lesion (TGL 2) was an ulcer with inflammation. Note: TGL 1 and 2 were from the genital and head areas respectively. Note: Dysplastic cells were in the stalk of the tumors on slides 13 and 14. [Hyperplasia TGLs = 1-11] [Inflammation TGLs = 2-12] [Ulcer TGLs = 2-12]</p>			
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Moderate Chronic Active, Mild Multiple Multiple
	[Squamous Cell Carcinoma TGLs = 4,5,7-13+14] [Squamous Cell Papilloma TGLs = 3,4,6-13+14]		
Spleen		Hematopoietic Cell Proliferation	Moderate
Stomach, Forestomach	[Squamous Cell Papilloma TGLs = 9-15]	Squamous Cell Papilloma	
Thymus		Atrophy	Marked
Tooth	[Odontogenic Tumor TGLs = 8-10]	Odontogenic Tumor	

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM: 274	TMT: 4	SEX: Female	DAY ON TEST: 86
	DOSE: 7600 NG/KG	DISP: Natural Death	HISTO: 0303184

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
Spleen			

OBSERVATIONS

* Liver	Inflammation	Minimal
Skin, Site of Application	Inflammation	Chronic Active, Mild
	Squamous Cell Carcinoma	
	Squamous Cell Papilloma	Multiple
[Squamous Cell Carcinoma TGLs = 1-10]		
[Squamous Cell Papilloma TGLs = 2,3,4-11+12]		
Thymus	Atrophy	Marked

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 275	TMT: 4	SEX: Female	DAY ON TEST: 187
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303185

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis
--------	----------------------	-------------------------

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation Inflammation Necrosis	Minimal Minimal Mild
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Papilloma Ulcer	Squamous, Mild Chronic Active, Moderate Multiple Moderate
	[Inflammation TGLs = 6-13]		
	[Squamous Cell Papilloma TGLs = 1,2,3,4,5-10+11+12]		
	[Ulcer TGLs = 6-13]		
Skin, SOA No Mass		Hyperplasia Inflammation	Squamous, Mild Chronic Active, Mild
Spleen		Hematopoietic Cell Proliferation	Marked
	[Hematopoietic Cell Proliferation TGLs = 7-4]		
Thymus		Atrophy	Marked

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	276	TMT:	4	SEX:	Female	DAY ON TEST:	183
		DOSE:	7600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303186

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
Spleen	Thymus		

OBSERVATIONS

* Liver	Inflammation	Minimal
	Pigmentation	Minimal
* Skin	Squamous Cell Papilloma	
Note: TGL 6 was from the genital area.		
Note: Dysplastic cells were present in the stalk of the tumor on slide 12.		
[Squamous Cell Papilloma TGLs = 6-13]		
Skin, Site of Application	Inflammation	Chronic Active, Mild
	Squamous Cell Carcinoma	
	Squamous Cell Papilloma	Multiple
[Squamous Cell Carcinoma TGLs = 5-12]		
[Squamous Cell Papilloma TGLs = 1,2,3,4-10+11+12]		

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 277	TMT: 4	SEX: Female	DAY ON TEST: 184
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303187

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver	Inflammation Necrosis Pigmentation	Mild Minimal Minimal
* Skin	Hyperplasia Inflammation	Squamous, Mild Chronic Active, Mild
<p>Note: The squamous cell carcinomas had a spindle cell component. Note: TGL 1 was from the genital area. Note: Dysplastic cells were present in the connective tissue beneath some of the tumors. Note: There was squamous hyperplasia and inflammation in the urogenital area that correlated with TGL 1. [Hyperplasia TGLs = 1-10]</p>		
Skin, Site of Application	Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma	Squamous, Moderate Chronic Active, Moderate Multiple Multiple
<p>[Squamous Cell Carcinoma TGLs = 2,3,5-11+12+13] [Squamous Cell Papilloma TGLs = 2,4,5,6-11+13]</p>		
Skin, SOA No Mass	Inflammation	Chronic Active, Minimal
Spleen	Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
Test Type: 26-WEEK
Route: SKIN APPLICATION
Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
TEF TRANSGENICS (PCB 126)
CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
Time Report Requested: 15:08:25
First Dose M/F: NA / 04/21/03
Lab: BAT

ANIMAL NUM:	278	TMT:	4	SEX:	Female	DAY ON TEST:	185
		DOSE:	7600 NG/KG	DISP:	Terminal Sacrifice	HISTO:	0303188

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus
--------	----------------------	-------------------------	--------

OBSERVATIONS

* Liver		Inflammation Necrosis Pigmentation	Mild Minimal Minimal
Skin, Site of Application		Inflammation Squamous Cell Papilloma	Chronic Active, Moderate Multiple
[Squamous Cell Papilloma TGLs = 1,2-10]			
Skin, SOA No Mass		Inflammation	Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Minimal

* PROTOCOL REQUIRED TISSUE

Control data contained within this report was collected on study 20201-01

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 279	TMT: 4	SEX: Female	DAY ON TEST: 186
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303189

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL

* Lung Thymus	Skin, Control Dermis	Skin, Control Epidermis	Skin, Soa No Mass
------------------	----------------------	-------------------------	-------------------

OBSERVATIONS

* Liver		Inflammation	Minimal
		Necrosis	Minimal
Skin, Site of Application		Hyperplasia	Squamous, Moderate
		Inflammation	Chronic Active, Mild
		Squamous Cell Carcinoma	Multiple
		Squamous Cell Papilloma	Multiple
	[Squamous Cell Carcinoma TGLs = 2,4-11+12]		
	[Squamous Cell Papilloma TGLs = 1,2,3,4,5-10+11+12]		
Spleen		Hematopoietic Cell Proliferation	Minimal
Stomach, Forestomach		Squamous Cell Papilloma	Multiple
	[Squamous Cell Papilloma TGLs = 6-13]		

* PROTOCOL REQUIRED TISSUE

TDMS No. 20201 - 02
 Test Type: 26-WEEK
 Route: SKIN APPLICATION
 Species/Strain: MICE/TG.AC HEMI

P14: INDIVIDUAL ANIMAL PATHOLOGY DATA
 TEF TRANSGENICS (PCB 126)
 CAS Number: 57465-28-8

Date Report Requested: 06/14/2006
 Time Report Requested: 15:08:25
 First Dose M/F: NA / 04/21/03
 Lab: BAT

ANIMAL NUM: 280	TMT: 4	SEX: Female	DAY ON TEST: 186
	DOSE: 7600 NG/KG	DISP: Terminal Sacrifice	HISTO: 0303190

ORGAN AND ACCOUNTABLE SITE STATUS

NORMAL			
* Lung	Skin, Control Dermis	Skin, Control Epidermis	Thymus

OBSERVATIONS

* Liver		Hematopoietic Cell Proliferation Pigmentation	Minimal Minimal
Skin, Site of Application		Hyperplasia Inflammation Squamous Cell Carcinoma Squamous Cell Papilloma Ulcer	Squamous, Mild Chronic Active, Moderate Multiple Multiple Moderate
	[Squamous Cell Carcinoma TGLs = 1,2,6-10+11+13] [Squamous Cell Papilloma TGLs = 3,4,5-11+12]		
Skin, SOA No Mass		Hyperplasia Inflammation	Squamous, Mild Chronic Active, Minimal
Spleen		Hematopoietic Cell Proliferation	Moderate
	[Hematopoietic Cell Proliferation TGLs = 7-4]		
Stomach, Forestomach		Squamous Cell Papilloma	
	[Squamous Cell Papilloma TGLs = 8-14]		

*** END OF REPORT ***

* PROTOCOL REQUIRED TISSUE